Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells

Leukemia Research

Volumn 30, Issue 9, 2006, Pages 1167-1175

  Deubzer, Hedwig ^a,b   Busche, Barbara ^c   Rönndahl, Gabi ^c   Eikel, Daniel ^d   Michaelis, Martin ^e   Cinatl, Jindrich ^e   Schulze, Sandra ^c   Nau, Heinz ^d   Witt, Olaf ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

Differentiation; HDAC; HL60; K562; Leukemia; p21Cip Waf; VPA

Indexed keywords

2 HEXYL 4 PENTYNOIC ACID; 2 PENTYL 4 PENTYNOIC AID; 3 PROPYL HEPTANOIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE; UNCLASSIFIED DRUG; VALPROIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

ANTICONVULSANTS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASES; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; VALPROIC ACID;

EID: 33745815657     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.01.009     Document Type: Article

References (46)

1. Blaheta R.A., Michaelis M., Driever P.H., and Cinatl Jr. J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25 (2005) 383-397
2. Fournel M., Trachy-Bourget M.C., Yan P.T., et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 62 (2002) 4325-4330
3. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
4. Van Lint C., Emiliani S., and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5 (1996) 245-253
5. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13 (2001) 477-483
6. Remiszewski S.W. Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr Opin Drug Discov Devel 5 (2002) 487-499
7. Yamashita Y., Shimada M., Harimoto N., et al. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103 (2003) 572-576
8. Wittich S., Scherf H., Xie C., et al. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J Med Chem 45 (2002) 3296-3309
9. Richon V.M., Emiliani S., Verdin E., et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95 (1998) 3003-3007
10. Chang T.H., and Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8 (2002) 1206-1212
11. Gottlicher M., Minucci S., Zhu P., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 (2001) 6969-6978
12. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., and Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61 (2001) 8492-8497
13. Ferrara F.F., Fazi F., Bianchini A., et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61 (2001) 2-7
14. Cinatl Jr. J., Cinatl J., Driever P.H., et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8 (1997) 958-963
15. Knupfer M.M., Hernaiz-Driever P., Poppenborg H., Wolff J.E., and Cinatl J. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 18 (1998) 3585-3589
16. Blaheta R.A., Hundemer M., Mayer G., et al. Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro. Cell Commun Adhes 9 (2002) 131-147
17. Cinatl Jr. J., Kotchetkov R., Blaheta R., Driever P.H., Vogel J.U., and Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 20 (2002) 97-106
18. Blaheta R.A., and Cinatl Jr. J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22 (2002) 492-511
19. Gurvich N., Tsygankova O.M., Meinkoth J.L., and Klein P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64 (2004) 1079-1086
20. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276 (2001) 36734-36741
21. Soldin S.J. Free drug measurements. When and why? An overview. Arch Pathol Lab Med 123 (1999) 822-823
22. Cloyd J.C., Dutta S., Cao G., Walch J.K., Collins S.D., and Granneman G.R. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res 53 (2003) 19-27
23. Bojic U., Elmazar M.M., Hauck R.S., and Nau H. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem Res Toxicol 9 (1996) 866-870
24. Bojic U., Ehlers K., Ellerbeck U., et al. Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre. Eur J Pharmacol 354 (1998) 289-299
25. U. Graveman, Dissertation. University of Hannover, 2002.
26. Nau H., and Loscher W. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam Appl Toxicol 6 (1986) 669-676
27. Levi M., Yagen B., and Bialer M. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives. Pharm Res 14 (1997) 213-217
28. Witt O., Sand K., and Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 95 (2000) 2391-2396
29. Witt O., Schulze S., Kanbach K., Roth C., and Pekrun A. Tumor cell differentiation by butyrate and environmental stress. Cancer Lett 171 (2001) 173-182
30. Witt O., Monkemeyer S., Ronndahl G., et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101 (2003) 2001-2007
31. Cinatl Jr. J., Cinatl J., Kotchetkov R., et al. Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs. Anticancer Res 20 (2000) 853-859
32. Chen J.S., Faller D.V., and Spanjaard R.A. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?. Curr Cancer Drug Targets 3 (2003) 219-236
33. Finzer P., Kuntzen C., Soto U., zur Hausen H., and Rosl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20 (2001) 4768-4776
34. Han J.W., Ahn S.H., Park S.H., et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60 (2000) 6068-6074
35. Kim Y.B., Lee K.H., Sugita K., Yoshida M., and Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18 (1999) 2461-2470
36. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood (2003)
37. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97 (2000) 10014-10019
38. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63 (2003) 3637-3645
39. Blaheta R.A., Nau H., Michaelis M., and Cinatl Jr. J. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 9 (2002) 1417-1433
40. Cinatl Jr. J., Cinatl J., Scholz M., et al. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7 (1996) 766-773
41. Witt O., Schmejkal S., and Pekrun A. Tributyrin plus all-trans-retinoic acid efficiently induces fetal hemoglobin expression in human erythroleukemia cells. Am J Hematol 64 (2000) 319-321
42. O'Loinsigh E.D., Gherardini L.M., Gallagher H.C., Foley A.G., Murphy K.J., and Regan C.M. Differential enantioselective effects of pentyl-4-yn-valproate on spatial learning in the rat, and neurite outgrowth and cyclin D3 expression in vitro. J Neurochem 88 (2004) 370-379
43. J. Volland, Dissertation. School of Veterinary Medicine Hanover, 2002.
44. Hauck R.S., Elmazar M.M., Plum C., and Nau H. The enantioselective teratogenicity of 2-normal-propyl-4-pentynoic acid (4-yn-VPA) is due to stereoselective intrinsic activity and not differences in pharmacokinetics. Toxicol Lett 60 (1992) 145-153
45. Finnin M.S., Donigian J.R., Cohen A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
46. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem 47 (2004) 467-474